Key Disclosure Details

  • The company has stated that it has not raised any funds through public issue, rights issue, preferential issue, or QIP (Qualified Institutions Placement) during the quarter ended March 31, 2026.
  • Furthermore, the company has no proceeds from any earlier issues outstanding for utilization as of the end of the same quarter.
  • Consequently, the requirement to file a statement of deviation/variation under Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is not applicable to the company for this period.

Date and Signatory

  • The letter is dated May 25, 2026.
  • It was digitally signed by Shailesh Siroya, an Authorised Signatory of Bal Pharma Ltd, on May 28, 2026, at 17:09:52 IST.

Financial Impact

No financial impact is associated with this disclosure, as it is a statement of non-applicability of a specific reporting requirement.